Treating Blood Pressure and Cholesterol in People at Risk for Dementia
Tests blood pressure and cholesterol medicines in 10 people at risk for dementia.
Key facts
- Who runs it
- University of Southern California
- Where
- Los Angeles, United StatesSee the site
- Trial code
- Registry title
- Vascular Intervention Strategies Trial for Alzheimer's
- Status
- Not yet recruiting
- Phase
- Phase 2
- People taking part
- 10 people, planned
- Started
- May 2026
- Expected to end
- Jun 2028
- Type of study
- Interventional
- Treatments tested
- Angiotensin Receptor Blockers (ARBs)
- Hydrophilic Statins or Non-Statin Alternative
- Record updated
- 4 May 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults aged 50 to 75 who carry the APOE ε4 gene, have high blood pressure and high cholesterol, and do not have dementia.
- Age
- 50 to 75 years
- Sex
- Men, and women after menopause
- Disease stage
- Systolic blood pressure 130-180 mm Hg and LDL-C 100-250 mg/dL (2.6–6.5 mmol/L). No dementia based on medical record review.
- Earlier treatment
- Cannot be taking medicines prescribed for dementia.
- Biomarker or test result
- APOE ε4 carrier (one or two copies of the gene variant).
Main reasons for not taking part
- History of stroke, symptomatic heart failure, or left ventricular ejection fraction below 35%
- End-stage kidney disease or eGFR below 20 ml/min/1.73m2
- Organ transplant
- Significant neurological disease such as Parkinson's disease, ALS, or multiple sclerosis
- Taking part in another clinical trial
The registry criteria, word for word
Show all 25 criteriaShow less
Who can take part
- APOE ε4 carrier (homozygote or heterozygote)
- LDL-C of 100-250 mg/dL
- Systolic blood Pressure (SBP) 130-180 mm Hg
- Age 50-75 years
- Fluency in English
- No dementia based on medical record review
- Male or post-menopausal female
Who cannot take part
- Contraindications to blood pressure and cholesterol lowering medications
- Receiving palliative or hospice care
- Receiving chronic opioid therapy
- Organ transplant
- Concurrent participation in another clinical trial
- Use of medications prescribed for dementia (e.g., aducanumab, donanemab, lecanemab, donepezil, galantamine, rivastigmine, memantine)
- Evidence of dementia based on medical record review
- Bipolar illness or schizophrenia
- Drug or alcohol disorder
- Any significant neurological disease (e.g., Parkinson's disease, amyotrophic lateral sclerosis, or multiple sclerosis)
- History of stroke, symptomatic HF or left ventricular ejection fraction < 35%
- ESRD or eGFR < 20 ml/min /1.73m2
- One minute standing SBP < 110 mm Hg
- Arm circumference prevents from accurate BP measurement with use of available devices
- Lost weight of > 10% unintendedly (within the past 6 months),
- Living in a skilled nursing or rehabilitation facility
- Severe loss of visual, hearing or communication ability
- Does not consent to be contacted or to have their medical record reviewed for research purposes
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 50 and 75 years old?
Where in United States
- Clinical Sciences Building (CSC)Los Angeles, United StatesContact: Hussein Yassine, MDNot yet recruiting
About the trial
What the trial wants to find out
The proposed pharmacist-led study is a feasibility pilot trial for the management of vascular risk factors of hypertension and hypercholesterolemia in 10 APOE ε4 carriers, 50-75, at-risk for dementia. All participants will receive angiotensin receptor blockers (ARBs) for high blood pressure, and hydrophilic statins (or a non-statin alternative) for high cholesterol over a six-month period.
The group in the trial
- Pharmacist-Led Vascular Risk Factor ManagementTreatment being tested
Participants receive pharmacist-led management of hypertension and hypercholesterolemia using angiotensin receptor blockers and hydrophilic statins (or non-statin alternatives) over six months.
Treatment: Angiotensin Receptor Blockers (ARBs) and Hydrophilic Statins or Non-Statin Alternative
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Vascular Intervention Strategies Trial for Alzheimer's (VISTA)
- Plain-language title
- Treating Blood Pressure and Cholesterol in People at Risk for DementiaGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Fit questions
- Built from NCT07447206, who can take part
- Record updated
- 4 May 2026